Competition for pediatric medical devices offers $50,000 in prizes

The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) has announced a competition to develop new technology for pediatric care. The competition will award up to six prizes of $50,000 for innovative medical devices.

The competition, which will be held at the Pediatric Device Innovation Symposium hosted by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System, invites researchers and clinicians to develop pediatric medical device concepts. Each device will be evaluated by a panel of judges, and winners will be awarded prizes as well as consultation services from the FDA-funded consortium.

"Receiving the symposium award was the start of great things for Velano, as it provided essential funding, expert services and validation that served as a bedrock for venture capital investment, FDA clearance and commercialization in hospitals nationwide," said Eric M. Stone, Velano Vascular's CEO and winner of the 2014 competition and a member of the 2017 symposium planning committee. "The Sheikh Zayed Institute and the competition are critical to the future of innovation for pediatric devices and we are grateful for their support and efforts to help our kids."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.